# Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

> **NCT01644968** · PHASE1 · COMPLETED · sponsor: **Providence Health & Services** · enrollment: 30 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Cohort 1 anti-OX40
- **DRUG:** Cohort 2 anti-OX40
- **DRUG:** Cohort 3 anti-OX40
- **BIOLOGICAL:** Tetanus Day 29
- **BIOLOGICAL:** Tetanus Day 1
- **BIOLOGICAL:** KLH Day 1
- **BIOLOGICAL:** KLH Day 29

## Key facts

- **NCT ID:** NCT01644968
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2009-05
- **Final completion:** 2017-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01644968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01644968, "Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01644968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*